415913-36-9

Upstream product

• 137756-89-9 4-(2-hydroxy ethyl)phenyl boronic acid 
• 4083-64-1 Tosyl isocyanate 
• 4654-39-1 4-bromophenethanol 
• 374675-64-6 pTsNCO 

Downstream Products

• 415906-87-5 2-[4-(5,6-dimethyl-1H-benzimidazol-1-yl)phenyl]ethyl (4-methylphenyl)sulfonylcarbamate 
• 616878-53-6 2-(4-(3-methyl-4-phenyl-1H-pyrazol-1-yl)phenyl)ethyl(4-methylphenyl) sulfonylcarbamate 

Relevant academic research and scientific papers

Pyrazole compounds as anti-inflammatory and analgesic agents

This invention provides a compound of the formula (I): wherein: R1 represents a hydrogen atom, an alkyl group, etc.; R2 represents a hydrogen atom, a halogen atom, etc.; R3 represents an alkyl group, etc.; R4 re

Imidazole compounds as anti-inflammatory and analgesic agents

This invention provides a compound of the formula (I): wherein: R1 represents a hydrogen atom, an alkyl group, etc.; R2 represents a hydrogen atom, a halogen atom, etc.; R3 represents a hydrogen atom, an alkyl group, etc.;

Use of EP4 receptor ligands in the treatment of IL-6 involved diseases

Methods of treating IL-6 involved diseases with EP4 receptor ligands, including EP4 receptor antagonists. Assays to determine the effect of test compounds on PGE2-induced whole blood cells activation.

EP4 RECEPTOR INHIBITORS TO TREAT RHEUMATOID ARTHRITIS

The invention features a method of treating rheumatoid arthritis in a mammal comprising administering an agent that inhibits prostaglandin EP4 receptor (EP4) activity. Also featured is a method of identifying agents that selectively inhibit EP4 activity in vivo.